4.6 Article

Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors

期刊

NEURO-ONCOLOGY
卷 24, 期 6, 页码 1020-1028

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noab276

关键词

ADC; ICI; IDH wild type; MRI; recurrent glioblastoma

资金

  1. American Cancer Society (ACS) Research Scholar Grant [RSG-15-003-01-CCE]
  2. University of California Research Coordinating Committee (BME)
  3. UCLA Jonsson Comprehensive Cancer Center Seed Grant
  4. UCLA SPORE in Brain Cancer [NIH/NCI 1P50CA211015-01A1]
  5. NIH/NCI [1R21CA223757-01]
  6. NIH-NIGMS Training Grant [GM008042]

向作者/读者索取更多资源

Elevated post-treatment ADC values may serve as an early imaging biomarker for predicting overall survival in patients with recurrent IDH wild-type GBM receiving immune checkpoint inhibitor treatment. This finding could potentially guide treatment decisions and prognosis assessment in these patients.
Background Diffusion MRI estimates of the apparent diffusion coefficient (ADC) have been shown to be useful in predicting treatment response in patients with glioblastoma (GBM), with ADC elevations indicating tumor cell death. We aimed to investigate whether the ADC values measured before and after treatment with immune checkpoint inhibitors (ICIs) and the changes in these ADC values could predict overall survival (OS) in patients with recurrent IDH wild-type GBM. Methods Forty-four patients who met the following inclusion criteria were included in this retrospective study: (i) diagnosed with recurrent IDH wild-type GBM and treated with either pembrolizumab or nivolumab and (ii) availability of diffusion data on pre- and post-ICI MRI. Tumor volume and the median relative ADC (rADC) with respect to the normal-appearing white matter within the enhancing tumor were calculated. Results Median OS among all patients was 8.1 months (range, 1.0-22.5 months). Log-rank test revealed that higher post-treatment rADC was associated with a significantly longer OS (median, 10.3 months for rADC >= 1.63 versus 6.1 months for rADC < 1.63; P = .02), whereas tumor volume, pretreatment rADC, and changes in rADC after treatment were not significantly associated with OS. Cox regression analysis revealed that post-treatment rADC significantly influenced OS (P = .02, univariate analysis), even after controlling for age and sex (P =.01, multivariate analysis), and additionally controlling for surgery after ICI treatment (P = .045, multivariate analysis). Conclusions Elevated post-treatment rADC may be an early imaging biomarker for OS benefits in GBM patients receiving ICI treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据